Drugmaker Pfizer filed a notice with the Securities and Exchange Commission estimating that its spinoff of its animal drug business called Zoetis will fetch $22 to $25 per share in the initial public offering.
Rarely do SEC filings have pictures of horses and piglets, kittens and chicks, so if you're into that kind of thing, a link is here.
Pfizer figures it can make more money from the animal drug business by spinning it off, but only partially. The Manhattan-based global pharmaceutical company, with a big operation in Collegeville, will keep about 80 percent of the shares and, theoretically, the profits.
The shares could begin trading on Feb. 1 on the New York Stock Exchange and will have the ticker symbol ZTS.